Veru Inc (VERU)
NASDAQ:VERU
Want to see VERU full AI Analyst Report?
VERU Stock Chart & Stats
$2.44
-$0.01(-1.91%)
At close: 4:00 PM EST
$2.44
-$0.01(-1.91%)
Day’s Range― - ―
52-Week Range$2.05 - $7.33
Previous CloseN/A
Volume1.22M
Average Volume (3M)3.79M
Market Cap
$47.35M
Enterprise Value$23.23M
Total Cash (Recent Filing)$30.76M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 06, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding16,050,320
10 Day Avg. Volume2,036,795
30 Day Avg. Volume3,787,484
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-203.23
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$25.00Price Target Upside924.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.
Potential PartnershipsPositive results from the QUALITY trial could help the company secure a partnership before advancing enobosarm into a pivotal program for the treatment of obesity.
Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.
Bears Say
Market CompetitionThe ease of administration for enobosarm (an oral drug) compares favorably to other competing treatment options that require intravenous administration.
Stock VolatilityA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.
Study ChallengesThe ongoing Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for the treatment of sarcopenic obesity is on track to report topline data in January 2025.
Veru News
VERU FAQ
What was Veru Inc’s price range in the past 12 months?
Veru Inc lowest stock price was $2.05 and its highest was $7.33 in the past 12 months.
What is Veru Inc’s market cap?
Veru Inc’s market cap is $47.35M.
When is Veru Inc’s upcoming earnings report date?
Veru Inc’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Veru Inc’s earnings last quarter?
Veru Inc released its earnings results on May 13, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.285 by $0.155.
Is Veru Inc overvalued?
According to Wall Street analysts Veru Inc’s price is currently Undervalued.
Does Veru Inc pay dividends?
Veru Inc pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru Inc dividends here
What is Veru Inc’s EPS estimate?
Veru Inc’s EPS estimate is -0.32.
How many shares outstanding does Veru Inc have?
Veru Inc has 16,050,320 shares outstanding.
What happened to Veru Inc’s price movement after its last earnings report?
Veru Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.285. Following the earnings report the stock price went down -0.441%.
Which hedge fund is a major shareholder of Veru Inc?
Currently, no hedge funds are holding shares in VERU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (924.59% Upside)
$25.00 (924.59% Upside)
Hedge Fund Trend
Decreased
By 653.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-51.15%
12-Months-Change
Fundamentals
Return on Equity
-53.43%
Trailing 12-Months
Asset Growth
31.86%
Trailing 12-Months
Company Description
Veru Inc
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
VERU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported meaningful clinical progress (positive Phase IIb functional results, active enrollment in a pivotal-feeding Phase IIb plateau study with interim readout expected Q1 2027) and materially improved near-term liquidity and expense trends. At the same time, Veru remains unprofitable, faces label and regulatory complexity (possible need for agent-specific studies or function/BMD endpoints), stiff competition from established GLP-1 players, and dependence on nonrecurring gains and an interim milestone for runway. On balance, the progress on clinical endpoints, the clear regulatory strategy contingencies, and improved cash position outweigh the operational and regulatory risks discussed.View all VERU earnings summariesVERU Stock 12 Month Forecast
Average Price Target
$25.00
▲(924.59% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
Currently, No data available
---